C. Ola Landgren, MD, PhD, explains how MRD negativity and newer therapies may move multiple myeloma care past the question of transplant eligibility.
Peter Voorhees, MD, discusses the CERVINO trial of the bispecific antibody etentamig that he is presenting at the IMS conference. Hans Lee, MD, Sarah Cannon Research Institute, explains new IMS/IMWG ...
The FDA has approved the kinase inhibitor lirafugratinib (Lyrfigtu) for adults with previously treated unresectable, locally ...
The FDA’s Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee has voted in favor of ...
FDA recommended a new survival-confirmatory trial prior to BLA submission, despite statistically significant ORR and PFS ...
Gurbakhash Kaur, MD, an assistant professor of internal medicine at Mount Sinai Health System, discusses the shifting role of autologous stem cell transplant (ASCT) in an era incr ...
Cure is defined as 5 years in complete remission without any anti-myeloma therapy, timed from treatment end rather than from initial response while still on treatment. Eligibility requires ≥4 ...
The imlunestrant label includes a warning and precaution for embryo-fetal toxicity, and the abemaciclib label includes ...
FDA labeling now reports a 49.7-month median DOR in TKI-naive advanced ROS1+ NSCLC from TRUST-I, based on 51-month median ...
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML ...
Martin Dietrich, MD, PhD, separates an agent working in the brain from an agent acting on the brain, and explains that ...
The FDA has approved aminolevulinic acid (ALA) hydrochloride topical gel, 10% (Ameluz), in combination with photodynamic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results